Evaluation of the clinical efficacy and safety of anti-HIV treatment with integrase inhibitor-containing schemes

Abstract

Background:
Integrase strand transfer inhibitors (INSTIs) are a cornerstone of modern antiretroviral therapy (ART) for HIV infection due to their potent antiviral activity and favorable safety profile. However, real-world data on their clinical efficacy and safety remain important to guide treatment choices.
Objective:
To evaluate the clinical efficacy and safety of antiretroviral regimens containing integrase inhibitors in patients with HIV infection.
Methods:
A retrospective/prospective cohort study was conducted involving [number] HIV-positive patients treated with INSTI-based regimens between [start year] and [end year]. Clinical outcomes, including viral suppression rates, CD4+ T-cell count recovery, and incidence of adverse events, were analyzed. Efficacy was assessed by proportion of patients achieving undetectable viral load (<50 copies/mL) at [timepoints]. Safety was evaluated based on reported adverse drug reactions and laboratory abnormalities.
Results:
Among [number] patients, [X%] achieved viral suppression at 24 weeks, increasing to [Y%] at 48 weeks. Median CD4+ count increased from [baseline] to [value] at 48 weeks (p < 0.001). The most common adverse events were [list, e.g., headache, insomnia, weight gain], with severe adverse events reported in [Z%] of patients. Treatment discontinuation due to toxicity was rare ([X%]).
Conclusion:
INSTI-containing antiretroviral regimens demonstrated high efficacy and acceptable safety profiles in HIV-infected patients. These findings support their continued use as first-line therapy. Ongoing monitoring for long-term adverse effects is recommended.
Keywords:
HIV, antiretroviral therapy, integrase inhibitors, efficacy, safety, clinical outcomes